Halo Therapeutics

Halo Therapeutics is a University of Bristol spinout developing structure-guided small-molecule medicines for infectious and metabolic diseases.

Its research combines cryo-electron microscopy, protein biophysics and computational chemistry to identify drug-binding pockets and design selective compounds. Its antiviral programme targets conserved fatty-acid binding sites on coronavirus spike proteins, while its metabolic research investigates receptor targets associated with obesity. The company advances proprietary therapeutic programmes using structural biology and molecular drug discovery.